AMES, Iowa, July 20 /PRNewswire/ -- NewLink Genetics Corporation announced today that it has secured $7.5 million in a Series D financing to accelerate the clinical development of its therapeutic cancer products. This financing involved additional funding from prior investors.
"NewLink has worked hard to become one of the leaders in the expanding field of cancer immunotherapy," said Dr. Charles Link, Chairman and Chief Executive Officer of NewLink Genetics Corporation. "The proceeds of this financing will allow us to both rapidly move our lead immunotherapy product for pancreatic cancer into pivotal clinical studies and to advance our IDO inhibitor, D-1MT, into multiple Phase 2 studies."
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company applying innovative approaches to create new therapeutic agents for patients with cancer and infectious diseases. Its technologies are designed to enhance the patient's immune system, enabling the body's immune cells to attack their intended target.
Contact NewLink Genetics Corporation Gordon Link, CFO, 515-296-4351
SOURCE NewLink Genetics Corporation